Endocrine therapy, involving selective estrogen receptor modulators, such as tamoxifen and fulvestrant, and aromatase inhibitors, such as anastrozole, letrozole, and exemestane, is used to treat hormone receptor (HR)-positive breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.